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Background: While headache is a common symptom among brain tumors patients, often patients with common
headache have concerns of being at risk for developing brain tumors. We aimed to disprove that migraine or
headache in general is associated with increased risk of developing brain tumors.
Methods: Prospective study among 39,534 middle-aged women, free of any cancer, and who provided information
on headache history at baseline. We followed participants for occurrence of medical record-confirmed brain tumors.
We ran multivariable-adjusted Cox proportional hazards models to evaluate associations between any headache,
migraine, and non-migraine headache with incident brain tumors. We further evaluated whether migraine
frequency and updated headache information during follow-up could be linked with brain tumors.
Results: A total of 13,022 (32.9%) women reported headache, of which 5,731 were classified as non-migraine
headache and 7,291 as migraine. During a mean follow-up of 15.8 years, 52 brain tumors were confirmed. The
multivariable-adjusted hazard ratios (95% confidence interval) for brain tumors were 1.33 (0.76-2.34) for any headache,
1.18 (0.58-2.41) for migraine and 1.53 (0.75-3.12) for non-migraine headache. The association for any headache was
further attenuated in time-varying analyses (1.15; 0.58-2.24). Those who experience migraine six times/year were
also not at increased risk of brain tumor (0.67; 0.13-3.32).
Conclusions: Results of this large, prospective cohort study in women do not provide evidence that headache in
general or migraine in particular are associated with the occurrence of brain tumors. Our data should reassure
patients with headache that brain tumor is not a long-term consequence of headache.
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Headache in general and migraine in particular are very
common disorders on the population level. While com-
mon headaches with typical pain characteristics are not
considered a risk factor for the development of brain
tumors, patients who experience frequent or severe
headache often worry about the possibility of a more
serious underlying condition such as a life-threatening
brain tumor [1,2].
Headache is a common symptom of brain tumors.
In a series of 206 patients with brain tumors, 48%
presented with headache [3]. Risk factor for presenting* Correspondence: tobias.kurth@u-bordeaux.fr
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history of headache. In particular of the brain tumor
patients with longstanding primary headache disorder
history, 64% presented with headache [3]. While numer-
ous articles report on specifics of headache as a symp-
tom of brain tumors [4-6], there is a lack of data on the
association of headache and migraine on the develop-
ment of brain tumors.
Thus, we aimed to provide evidence that headache in
general and migraine in particular are not associated
with the development of brain tumors. To study our aims,
we utilized data from the prospective Women’s Health
Study which collected information on headache and mi-
graine at baseline and confirmed brain tumor cases during
a mean of 15.8 years of follow-up.Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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Study population
The Women’s Health Study was a randomized double
blind placebo controlled trial to test the risks and bene-
fits of low dose aspirin and vitamin E in the primary
prevention of cardiovascular disease and cancer among
apparently healthy women. The design, methods, and re-
sults have been described in detail previously [7-9]. Briefly,
a total of 39,876 US female health care professionals aged
45 years or older at study entry (1992–1995) without a
history of cardiovascular disease, cancer, or other major
illnesses were randomly assigned to receive active aspirin
(100 mg on alternate days), active vitamin E (600 IU on
alternate days), both active agents, or both placebos. All
participants provided written informed consent, and the
institutional review board of Brigham and Women’s
Hospital, Boston, MA, approved the WHS. Baseline
information was self-reported and collected by a mailed
questionnaire that asked about several cardiovascular
risk factors and lifestyle variables. Twice in the first year
and yearly thereafter, participants were sent follow-up
questionnaires asking about study outcomes and other
information during the study period. The trial ended in
March 2004. At this time point, 89% of the initially ran-
domized women who were still alive were eligible and
willing to enter observational follow-up. For the pur-
pose of this analysis, we included information from the
time of randomization through October 2013.
Assessment of headache and migraine
At baseline the women were asked “Have you ever had
migraine headaches?” and “In the past year, have you
had migraine headaches?” Women who experienced mi-
graine headaches within the past year were asked for fur-
ther details including “What is the approximate frequency
of your migraines?” with possible response options of
daily, weekly, monthly, every other month, and less than 6
times per year and “Do your migraines have any of the
following characteristics?” The response options included
“Aura or any other indication a migraine is coming” which
was used to classify women who experience migraine with
aura. Since the baseline questionnaire did not ask about
non-migraine headache, we used information from the
six-month questionnaire to assess headache. On the
six-month questionnaire, women were asked if they had
any headache since the baseline questionnaire. Using
the women’s responses to these questions, we divided
them into the following groups: any history of migraine
(women who reported ever experiencing migraine head-
ache), history of non-migraine headache (women who
reported experiencing headache but did not report mi-
graine headaches) and no history of headache (women
who reported no history of migraine headache or non-
migraine headache). We also created an “any headache”category which included the women in both the any his-
tory of migraine category and the history of non-migraine
headache category. Women with any history of migraine
were further divided into the following categories: “mi-
graine with aura” (women who reported migraine within
the past year and who reported the presence of aura or
any indication that migraine is coming); “migraine without
aura”; and “past history of migraine” (women who re-
ported ever having migraines but not within the past year).
Women who reported experiencing migraine within the
past year were also categorized according to the frequency
of their attacks (<6 times per year versus ≥6 time per
year). A previous study in the Women’s Health Study [10]
has shown good agreement between self-reported mi-
graine without aura and classification of migraine without
aura based on the International Classification of Headache
Disorders criteria [11]. In particular, we have shown that
87% of women who reported migraine could be classified
as “probable migraine” [10].
Brain tumor assessment
Participants were asked to report tumor diagnoses on each
follow-up questionnaire. Medical records and other rele-
vant information were obtained for all self-reported brain
tumor cases and reviewed by an Endpoints Committee of
physicians to confirm the medical diagnosis. Deaths of
participants were identified through family member re-
ports, postal authorities, or a search of the National Death
Index. For the purpose of this analysis, only confirmed
first primary brain tumor events were included.
Statistical methods
Of the 39,876 participants, 119 women with missing
migraine information at baseline were excluded. We
additionally excluded 223 women who developed any
tumor prior to the 6-month questionnaire or did not
return the six-month questionnaire, leaving a total of
39,534 women free of any tumor for this analysis.
Baseline characteristics of participants according to head-
ache and migraine status were compared by contrasting
means or frequencies.
Person-time was calculated from the date of the
6-month questionnaire to the date of first brain tumor
diagnosis, date of first any other tumor diagnosis, death
from any cause, last contact, or end of follow-up, whatever
occurred first.
We used Cox proportional hazards models to evaluate
the association of any headache, non-migraine headache,
and any history of migraine on brain tumor incidence.
We calculated age-and multivariable-adjusted hazard
ratios (HRs) and their corresponding 95% confidence
intervals (CIs).
To determine whether the risk for developing brain
tumor differs according to migraine subtypes, we calculated
Table 1 Baseline characteristics according to headache








Age, yrs, mean 55.1 (7.3) 53.6 (6.4) 53.5 (6.4)
Body mass index,
kg/m2, mean
25.9 (5.0) 26.3 (5.3) 26.2 (5.1)
Smoking, %
Never 50.4 51.5 53.4
Past 36.2 36.0 34.0
Current 13.2 12.3 12.4
Alcohol
consumption, %
Rarely never 43.6 48.2 47.8
1-3 drinks/month 12.8 13.3 14.4
1-6 drinks/week 32.3 30.4 29.7
≥1 drinks/day 11.2 8.1 8.1
Exercise, %
Rarely/never 38.4 37.7 38.7
<1/week 19.1 20.7 22.2
1-3 times/week 31.2 32.7 29.6
≥4 times/week 11.3 8.9 9.5
Postmenopausal
status, %
Premenopausal 26.9 30.1 28.0
Postmenopausal 56.4 49.7 50.2
Unsure 16.6 20.0 21.6
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graine with aura, migraine without aura, or past history
of migraine) and brain tumor.
We also performed exploratory analyses in which we ran
multivariable-adjusted models stratified by age (<55 years
of age compared to ≥55 years of age).
To explore whether migraine attack frequency is asso-
ciated with brain tumor risk, we calculated age-adjusted
HRs for any brain tumor according to the reported
number of migraine attacks among the 5,081 active
migraineurs who provided attack frequency information.
The multivariable-adjusted models were adjusted for
age, body mass index (BMI) (<25, 25–29.9, ≥30 kg/m2),
alcohol consumption (rarely/never, 1–3 drinks/month, 1–6
drinks/week, ≥1 drink/day), smoking status (never, past,
current), postmenopausal status (premenopausal, post-
menopausal, uncertain), and exercise (rarely/never, <1
time/week, 1–3 times/week, ≥4 times/week). Additional
adjustment for randomized treatment assignments did
not change the effect estimates of migraine and non-
migraine headache on any brain tumor.
Less than 100 people had missing information on any
of our covariates. Those with missing information on
alcohol consumption or exercise were assigned to the
reference category (rarely/never). Those with missing infor-
mation on smoking were assigned to the past smoking cat-
egory and those missing information on postmenopausal
status were assigned to the uncertain category. Women
missing BMI were assigned the mean BMI (26.1 kg/m2).
In secondary analyses, we updated the information on
any headache during follow-up. On each follow-up ques-
tionnaire, participants were asked about headache or mi-
graine. Those who did not report headache or migraine
in the past were re-categorized to any headache if they
indicated headache or migraine during follow-up.
The proportional hazards assumption was tested by
including an interaction term for headache status and
logarithm of follow-up time for any brain tumor in age-
adjusted models. We found no statistically significant
violation.
For all analyses, we used SAS (version 9.3, SAS Institute
Inc. Cary, NC). All p-values were 2-tailed and p-value <0.05
was considered statistically significant.
Results
Of the 39,534 participants, 13,022 (32.9%) women re-
ported headache, of which 5,731 were classified as non-
migraine headache and 7,291 as migraine headache.
In Table 1, baseline characteristics of participants accord-
ing to headache status are presented. Those who experi-
ence migraine or non-migraine headache were younger,
more likely to be never smokers and to rarely consume
alcohol, and less likely to exercise frequently or be post-
menopausal than those without headache.During a mean follow-up time of 15.8 years, 52 brain
tumor cases were confirmed. There were 36 gliomas or
glioblastomas, 7 astrocytomas, 3 meningiomas, 1 oligo-
dendroglioma, and 5 other neoplasms. In Table 2, age-
and multivariable-adjusted HRs (95% CI) for brain tumor
according to headache status are presented. Those who
experience any headache had a hazard ratio of 1.33 (95%
CI: 0.76, 2.34) compared to those with no headache after
multivariable adjustment. We also did not observe a
significant increase in the risk of brain tumor when we
examined those with non-migraine headache (HR = 1.53;
95% CI: 0.75, 3.12) or any migraine (HR = 1.18; 95% CI:
0.58, 2.41). The association for any headache was further
attenuated in the time-varying analysis (1.15; 0.59-2.24).
Stratification by age demonstrated a slightly higher risk
of brain tumor among those less than 55 years of age,
but none of the increases were statistically significant
(Table 3).
We also explored whether the risk of brain tumor varies
by migraine subtype in age-adjusted analyses. We ob-
served 2 cases of brain tumor in those with a past history
of migraine (N = 2,145), 7 cases in those with migraine
without aura (N = 3,096) and 1 case in those with migraine
Table 2 Age- and multivariable* adjusted hazard ratios (95% confidence intervals) of brain tumor according to


























Age-adjusted 32 1.00 (ref) 20 1.35 (0.77, 2.37) 10 1.53 (0.75, 3.13) 10 1.21 (0.59, 2.47)
Multivariable adjusted* 32 1.00 (ref) 20 1.33 (0.76, 2.34) 10 1.53 (0.75, 3.12) 10 1.18 (0.58, 2.41)
*Adjusted for age, body mass index (BMI) (<25, 25–29.9, ≥30 kg/m2), alcohol consumption (rarely/never, 1–3 drinks/months, 1–6 drinks/week, ≥1 drink/day),
smoking status (never, past, current), postmenopausal status (premenopausal, postmenopausal, uncertain), and exercise (rarely/never, <1 time/week, 1–3 times/
week, ≥4 times/week).
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95% CI: 0.17, 2.88), migraine without aura (HR = 1.88,
95% CI: 0.84, 4.23), and migraine with aura (HR = 0.41,
95% CI: 0.06, 2.97) were not associated with a significant
increase in the risk of brain tumor in age-adjusted models.
Of those who experienced active migraine at baseline,
3,293 women experienced migraines less than six times
per year of which 6 developed brain tumor and 1,788
women experienced migraine six or more times per year
of which 2 developed brain tumor. Those who experi-
ence migraine six or more times per year were not at
increased risk of brain tumor compared to those who ex-
perience migraine less than six times per year (HR = 0.67,
95% CI: 0.13, 3.32) in age-adjusted models.
Discussion
In this large, prospective study of initially apparently
healthy women, we did not find evidence that any head-
ache history is associated with increased risk of brain
tumors. The lack of association was apparent for women
with any headache history, non-migraine headache, or
migraine headache. The results were further attenuated
when we updated information on any headache during
follow-up. We also found no association for women
who indicated they experienced more frequent migraine
attacks. While numbers were low, we also did not find
any evidence that migraine aura status was associated
with increased risk of brain tumor incidence.Table 3 Multivariable* adjusted hazard ratios (95% confidenc













<55 years of age at baseline
(N = 23,849)
13 1.00 (ref) 12 1.57
≥55 years of age at baseline
(N = 15,685)
19 1.00 (ref) 8 1.10
*Adjusted for age, body mass index (BMI) (<25, 25–29.9, ≥30 kg/m2), alcohol consum
smoking status (never, past, current), postmenopausal status (premenopausal, postm
week, ≥4 times/week).Comparison with other studies
While there are numerous studies which report head-
ache as a symptom of brain tumors [3,4,12,13], to the
best of our knowledge, no other population-based study
has evaluated the role of headache as risk factor for
the development of brain tumor. A recent review of
the literature summarized the evidence for headache as
a symptom of brain tumors [13]. The authors found that
the headaches associated with brain tumors often satisfy
the criteria for a primary headache category such as mi-
graine or tension-type headache but these headaches are
often observed in patients with a longstanding history of
primary headache disorders [3].
Despite the lack of scientific evidence, there are reports
on webpages describing fears of brain tumor development
for patients with headache disorders, specifically for pa-
tients with chronic headache forms [1,2]. We hope that
the lack of association of headache or migraine with the
development of brain cancer presented in this study
will help to remove this fear for patients and contribute to
a more rational discussion. Of course our data do not
contradict the fact that headache is a symptom of brain
tumors or that brain tumors can trigger headache disor-
ders [13,14].
Several other studies have evaluated the association be-
tween migraine and overall cancer and breast cancer in par-
ticular. In a case–control study nested within the General


















(0.72, 3.46) 6 1.79 (0.68, 4.72) 6 1.40 (0.53, 3.69)
(0.48, 2.53) 4 1.28 (0.43, 3.78) 4 0.96 (0.33, 2.85)
ption (rarely/never, 1–3 drinks/months, 1–6 drinks/week, ≥1 drink/day),
enopausal, uncertain), and exercise (rarely/never, <1 time/week, 1–3 times/
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for patients with migraine [15]. While this association
was adjusted for major other comorbid conditions and
risk factors, increased healthcare utilization by patients
with migraine may have accounted for this increased
risk of cancer [15].
There is an ongoing discussion about whether patients
with migraine are at decreased risk of developing breast
cancer [16] based on the involvement of hormonal
factors in migraine and breast cancer. However, recent
population-based findings did not confirm a reduced
breast cancer risk [17,18]. With regard to brain cancer,
hormonal factors are very unlikely to play a role in the
development of brain tumors [19]. We are also not
aware of any other plausible biological mechanism that
could link headache in general or migraine in particular
with brain tumor development.Strengths and limitations
Our study has several strengths including its large size,
standardized assessment of headache disorders at base-
line, medical record confirmation of diagnoses of brain
tumors, and the homogeneity of the cohort assuring
similar access to medical care.
Several limitations have to be considered when inter-
preting our results. First, headache and migraine were
self-reported and misclassification is possible. However,
at least for migraine without aura, we have shown good
agreement with standard diagnostic criteria [10]. In
addition, migraine classification was done years before
brain tumor diagnosis, which would result in non-
differential bias. Second, although the Women’s Health
Study is a large cohort, only few brain tumor cases
occurred resulting in reduced power to detect a signal.
Lastly, our study population consisted of female health
professionals aged 45 years and older at baseline. Thus,
our data may not generalize other settings. However, we
have no reason to believe that the mechanisms by which
headache potentially affects incident brain tumor differs
in our study population.Clinical implications
We believe that the lack of association between any
headache history and risk of developing brain tumor is
of great importance for patients and their treating phy-
sicians. Our data should reassure patients that a primary
headache disorder will not result in a brain tumor. Of
course headache can be an early symptom of brain
cancer but this secondary induced headache differs in
symptoms and course from primary headache [14]. In
our study, we did not study whether headache is a
symptom reported by participants at the time of brain
tumor incidence.Conclusions
In conclusion, results of our prospective cohort study do
not indicate that headache in general or migraine in
particular are risk factors for the development of brain
tumors. We did not study headache as a symptom of
brain tumors or whether brain tumors trigger specific
headache forms. Patients with headache in general and
migraine in particular should be reassured that brain
tumor is very likely not a consequence of their disorder.
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